DB05746InvestigationalSmall molecule
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207... The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.
- Primary indication
- Investigated for use/treatment in glaucoma and ocular hypertension.Curator reviewed
- Code names
- PF-03187207
What you can answer from here — as of April 02, 2025
Which companies are running trials of PF-03187207, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account